Nasdaq

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
PharmiWeb

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System ...

MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy and safety of amlenetug in the treatment of Multiple System Atrophy (MSA) H. Lundbeck A/S ...
Nasdaq

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in ...

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...